MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
Depository Receipt · US6177602025 · MOR · A2JJ5S (XNAS)
Overview
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 4,35 % -37,69 %

Company Profile for MORPHOSYS AG - AMERICAN DEPOSITARY SHARES Depository Receipt

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Company Data

Name MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
Company MorphoSys AG
Symbol MOR
Website https://www.morphosys.com
Primary Exchange XNAS NASDAQ
WKN A2JJ5S
ISIN US6177602025
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Mr. Arkadius Pichota M.B.A., Ph.D.
Market Capitalization 3 Mrd.
Country Germany
Currency USD
Employees 0,5 T
Address Semmelweisstrasse 7, 82152 Planegg
IPO Date 2018-04-19

Ticker Symbols

Name Symbol
Frankfurt MOR2.F
NASDAQ MOR

More Shares

Investors who MORPHOSYS AG - AMERICAN DEPOSITARY SHARES hold also have the following shares in their portfolio:
DEKA NOK FESTZINS 19/23
DEKA NOK FESTZINS 19/23 Bond
Summit Hotel Properties, Inc.
Summit Hotel Properties, Inc. Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025